Apimeds Pharmaceuticals US (APUS) Shares Outstanding (Weighted Average) (2023 - 2025)

Apimeds Pharmaceuticals US has reported Shares Outstanding (Weighted Average) for 3 years, with the latest figure at $10.9 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 37.68% year-over-year to $10.9 million; the trailing twelve-month figure through Dec 2025 stood at $10.9 million (up 37.68% YoY), and the FY2025 full-year result was $10.9 million, up 37.68% from the prior year.
• Shares Outstanding (Weighted Average) for Q4 2025 stood at $10.9 million, up from $10.3 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $10.9 million in Q4 2025, with the low at $4.6 million in Q4 2023.
• Historically, Shares Outstanding (Weighted Average) has averaged $8.4 million across 3 years, with a median of $7.9 million in 2024.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Weighted Average) surged 71.89% — and 2025, when it changed 0.0%.
• Apimeds Pharmaceuticals US's Shares Outstanding (Weighted Average) stood at $4.6 million in 2023, then soared by 71.89% to $7.9 million in 2024, then surged by 37.68% to $10.9 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $10.9 million (Q4 2025), $10.3 million (Q3 2025), and $10.4 million (Q2 2025), per Business Quant data.